Literature DB >> 28179279

Role of RUNX1 in hematological malignancies.

Raman Sood1, Yasuhiko Kamikubo2, Paul Liu1.   

Abstract

RUNX1 is a member of the core-binding factor family of transcription factors and is indispensable for the establishment of definitive hematopoiesis in vertebrates. RUNX1 is one of the most frequently mutated genes in a variety of hematological malignancies. Germ line mutations in RUNX1 cause familial platelet disorder with associated myeloid malignancies. Somatic mutations and chromosomal rearrangements involving RUNX1 are frequently observed in myelodysplastic syndrome and leukemias of myeloid and lymphoid lineages, that is, acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelomonocytic leukemia. More recent studies suggest that the wild-type RUNX1 is required for growth and survival of certain types of leukemia cells. The purpose of this review is to discuss the current status of our understanding about the role of RUNX1 in hematological malignancies.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28179279      PMCID： PMC5391618          DOI： 10.1182/blood-2016-10-687830

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  202 in total

Review 1.  RUNX1 translocations and fusion genes in malignant hemopathies.

Authors:  Etienne De Braekeleer; Nathalie Douet-Guilbert; Frédéric Morel; Marie-Josée Le Bris; Claude Férec; Marc De Braekeleer
Journal:  Future Oncol       Date:  2011-01       Impact factor: 3.404

2.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection.

Authors:  E Renate Panzer-Grümayer; Giovanni Cazzaniga; Vincent H J van der Velden; Laura del Giudice; Martina Peham; Georg Mann; Conny Eckert; Andre Schrauder; Giuseppe Germano; Jochen Harbott; Giuseppe Basso; Andrea Biondi; Jacques J M van Dongen; Helmut Gadner; Oskar A Haas
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

4.  High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

Authors:  Sanne Lugthart; Ellen van Drunen; Yvette van Norden; Antoinette van Hoven; Claudia A J Erpelinck; Peter J M Valk; H Berna Beverloo; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

5.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

Review 6.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.

Authors:  Motomi Osato
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

Review 7.  The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.

Authors:  E Ohlsson; M B Schuster; M Hasemann; B T Porse
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

8.  The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Authors:  Rajani K Vangala; Marion S Heiss-Neumann; Janki S Rangatia; Sheo M Singh; Claudia Schoch; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

9.  The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion.

Authors:  S P Romana; M Mauchauffé; M Le Coniat; I Chumakov; D Le Paslier; R Berger; O A Bernard
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

10.  miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells.

Authors:  Eric R Lechman; Bernhard Gentner; Stanley W K Ng; Erwin M Schoof; Peter van Galen; James A Kennedy; Silvia Nucera; Fabio Ciceri; Kerstin B Kaufmann; Naoya Takayama; Stephanie M Dobson; Aaron Trotman-Grant; Gabriela Krivdova; Janneke Elzinga; Amanda Mitchell; Björn Nilsson; Karin G Hermans; Kolja Eppert; Rene Marke; Ruth Isserlin; Veronique Voisin; Gary D Bader; Peter W Zandstra; Todd R Golub; Benjamin L Ebert; Jun Lu; Mark Minden; Jean C Y Wang; Luigi Naldini; John E Dick
Journal:  Cancer Cell       Date:  2016-04-11       Impact factor: 31.743
View more
  127 in total

Review 1.  Off to a Bad Start: Cancer Initiation by Pluripotency Regulator PRDM14.

Authors:  Lauren J Tracey; Monica J Justice
Journal:  Trends Genet       Date:  2019-05-23       Impact factor: 11.639

2.  Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.

Authors:  Chun Guo; Jian Li; Nickolas Steinauer; Madeline Wong; Brent Wu; Alexandria Dickson; Markus Kalkum; Jinsong Zhang
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

3.  TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia.

Authors:  Stefanie V Junk; Norman Klein; Sabine Schreek; Martin Zimmermann; Anja Möricke; Kirsten Bleckmann; Julia Alten; Elif Dagdan; Gunnar Cario; Christian P Kratz; Martin Schrappe; Martin Stanulla
Journal:  Haematologica       Date:  2019-07-09       Impact factor: 9.941

4.  DNA Rchitect: an R based visualizer for network analysis of chromatin interaction data.

Authors:  R N Ramirez; K Bedirian; S M Gray; A Diallo
Journal:  Bioinformatics       Date:  2020-01-15       Impact factor: 6.937

Review 5.  Genetic defects in hematopoietic transcription factors and predisposition to acute lymphoblastic leukemia.

Authors:  Yoshihiro Gocho; Jun J Yang
Journal:  Blood       Date:  2019-07-16       Impact factor: 22.113

6.  Accurate germline RUNX1 variant interpretation and its clinical significance.

Authors:  Simone Feurstein; Liying Zhang; Courtney D DiNardo
Journal:  Blood Adv       Date:  2020-12-22

7.  Introduction to the review series on transcription factors in hematopoiesis and hematologic disease.

Authors:  David M Bodine
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

Review 8.  Diagnostic molecular techniques in haematology: recent advances.

Authors:  Aikaterini Koutsi; Elisavet-Christina Vervesou
Journal:  Ann Transl Med       Date:  2018-06

9.  High-throughput sequencing for rapid diagnosis of inherited platelet disorders: a case for a European consensus.

Authors:  Alan T Nurden; Paquita Nurden
Journal:  Haematologica       Date:  2018-01       Impact factor: 9.941

10.  Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma.

Authors:  Seiichiro Katagiri; Hideki Makishima; Kenko Azuma; Yasuhito Nannya; Yuu Saitoh; Seiichiro Yoshizawa; Daigo Akahane; Hiroaki Fujimoto; Yoshikazu Ito; Ravi Velaga; Tomohiro Umezu; Junko H Ohyashiki; Seishi Ogawa; Kazuma Ohyashiki
Journal:  Haematologica       Date:  2019-11-07       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.